Evidence map›Paper›PMID 40603574›Full record

ArticleScientific reports2025

Etiological mechanisms underlying the hazard factors and inflammatory bowel disease: a prospective cohort study.

Yi Tao, Yongjia Li, Tianyi Zhou, Lei Zhao, Pan Li, Minghong Sun, Lijuan Zhang, Lihong Yang, Ting Chen, Xuemei Lian and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi Tao *Phase I clinical trial ward, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yongjia Li *School of Public Health, Chongqing Medical University, Chongqing, 400016, China.
Tianyi Zhou *School of Public Health, Chongqing Medical University, Chongqing, 400016, China.
Lei ZhaoCentre for Lipid Research, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China.
Pan LiDepartment of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Minghong SunPhase I clinical trial ward, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Lijuan ZhangPhase I clinical trial ward, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Lihong YangPhase I clinical trial ward, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ting ChenChongqing Center for Disease Control and Prevention, Chongqing, 400700, China.
Xuemei LianSchool of Public Health, Chongqing Medical University, Chongqing, 400016, China. xuemeilian@cqmu.edu.cn.
Xiaoni ZhongSchool of Public Health, Chongqing Medical University, Chongqing, 400016, China. zhongxiaoni@cqmu.edu.cn.

Funding

Future Medical Youth Innovation Team Development Support Program of Chongqing Medical University W0085National Natural Science Foundation of China 82404767
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a progressively advancing immune-mediated disorder characterized by intricate pathophysiological features. Despite extensive research, the mechanisms linking various risk factors to the development of IBD remain incompletely understood. We conducted analyses within a prospective cohort of unrelated European individuals, utilizing data from the UK Biobank. This cohort had over a decade of follow-up and included more than 500,000 participants aged between 37 and 73 years at recruitment, which took place between 2006 and 2010. A multivariate Cox proportional model was employed to investigate the impact of different risk factors on the incidence of IBD. Additionally, we examined the relationship between 220 peripheral biomarkers and the occurrence of IBD. Finally, we constructed a structural equation model to elucidate the complex pathogenic mechanisms and interactions among genetic risks, lifestyle factors, dietary habits, comorbidities, and immune metabolism in the progression of IBD. A total of 461,454 participants were included in the analysis, of whom 3,494 were newly diagnosed with IBD during the follow-up period. The multivariate Cox proportional model revealed the hazardous roles of polygenic risks, lifestyle factors, diet, immune metabolism, and pre-existing diseases. Specifically, insomnia, major illness-related dietary changes, and unhealthy dietary habits were associated with a 23%, 87%, and 15% increased risk of IBD, respectively. Smoking was found to increase the risk of IBD by 46% compared with never smoking. Comorbidities such as stomach pain, back pain, knee pain, and hip pain increased the risk of IBD by 128% , 27% , 22% and 17% respectively. Moreover, exposure to tobacco, lower educational degree, higher neuroticism score and seen a psychiatrist for nerves, anxiety, tension or depression before also identified as hazard risks. Among the 220 peripheral biomarkers analyzed, we found that cholesterol has the potential to become a new biomarker for predicting IBD. In terms of the pathways leading to IBD, a poor lifestyle contributed to a 5.2% increase in IBD risk, genetic risks accounted for a 2.7% increase, and immune metabolism was associated with a 1.1% increase. We developed an etiological model of IBD that elucidates the complex underlying mechanisms and highlights immune metabolism as the primary mediator in the emergence of IBD.

Indexed as

Inflammatory Bowel DiseasesAdultAgedBiomarkersFemaleHumansIncidenceLife StyleMaleMiddle AgedProportional Hazards ModelsProspective StudiesRisk FactorsSmokingBiomarkersHazard factorsIBDPathogenic factorsPeripheral markers

Identifiers

PMID40603574
PMCPMC12223230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.